.svg){kind=small}
The study comprised a total of 232 randomised males and it measured, as its primary endpoint, improvement in the erectile function ("EF") domain score of the International Index of Erectile Function ("IIEF"), the scoring system used for the approval of PDE5 inhibitors such as Viagra®. The study was of a placebo-controlled, double blind, home use, crossover design.View news article
.avif)
Latest news
Participant-Centred Recruitment and Retention: Driving Faster Answers in Clinical Trials.
December 18, 2025
Richmond Pharmacology is proud to announce the publication of an editorial by Elizabeth Romano, Director of Communications and Participant Engagement, in the Winter 2025 issue of the Journal for Clinical Studies.
Read moreEvents
JSCPT 2025
5 – 6 December 2025
Richmond Pharmacology will attend JSCPT 2025 in Tokyo, represented by their leadership team. Topics include early-phase studies, bridging studies between Europe and Asia, gene and RNA-based therapy development, and cross-border collaboration.
View event
